Despite tumors’ ability to escape from immunosurveillance by expression of PD-L1 within the tumor microenvironment, there is renewed hope in the field of cancer immunotherapy with the promising approach of using immune checkpoint inhibitors (ICIs) to reinvigorate this antitumor immunity [8,9,10]. This evidence concerns the gene CD274 and cancer.